This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest Eventse-therapeutics（ETX）株式概要Engages in drug discovery research activities in the United Kingdom. 詳細ETX ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析収益が 100 万ドル未満 ( £340K )過去5年間で収益は年間25.6%減少しました。 UK市場と比較した過去 3 か月間の株価の変動意味のある時価総額がありません ( £53M )すべてのリスクチェックを見るETX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUK£Current PriceUK£0.091.5k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-12m918k2016201920222025202620282031Revenue UK£918.4kEarnings UK£166.9kAdvancedSet Fair ValueView all narrativese-therapeutics plc 競合他社Tissue Regenix GroupSymbol: AIM:TRXMarket cap: UK£5.2mFaron Pharmaceuticals OySymbol: AIM:FARNMarket cap: UK£82.8mHemogenyx PharmaceuticalsSymbol: LSE:HEMOMarket cap: UK£46.9mBioventixSymbol: AIM:BVXPMarket cap: UK£87.5m価格と性能株価の高値、安値、推移の概要e-therapeutics過去の株価現在の株価UK£0.0952週高値UK£0.2452週安値UK£0.08ベータ0.431ヶ月の変化-28.00%3ヶ月変化-41.18%1年変化-29.27%3年間の変化-65.78%5年間の変化332.69%IPOからの変化-86.67%最新ニュースお知らせ • Apr 11e-therapeutics plc Considers Switching Its Listing to New YorkShares of e-therapeutics plc fell 12% after the company said it is considering switching its listing to New York, a move that would deal a further blow to the London bourse following a spate of defections in recent months. The provider of digital technology for drug discovery also said April 10, 2024 that it raised GBP 28.9 million ($36.6 million) via a high-premium share subscription by its two largest shareholders. Shares at 0752 GMT were down 1.50 pence at 11.0 pence. They are currently down 25% over the past 12 months. e-Therapeutics is seeking shareholder approval to cancel its current listing on London's junior AIM, saying it doesn't believe it accurately reflects its value and is a hindrance to its plans given a significant reduction in liquidity and access to capital. It also said it believes a listing on U.S. Nasdaq will provide a higher valuation, but cautioned that there is no certainty the listing will be achievable in any given time frame. The London delisting plan has the support of shareholders owing 46.68% of its shares, it said. e-Therapeutics has called a general meeting for April 29 to seek approval to delist its shares, and if approved, expects cancellation to become effective from May 9.お知らせ • Apr 10e-therapeutics plc, Annual General Meeting, Apr 29, 2024e-therapeutics plc, Annual General Meeting, Apr 29, 2024, at 11:30 Coordinated Universal Time. Location: Unit 4B, Floor 4, 4 Kingdom Street, Paddington Central London United KingdomNew Risk • Feb 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: UK£77.1m (US$97.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (UK£340k revenue, or US$430k). Minor Risk Market cap is less than US$100m (UK£77.1m market cap, or US$97.7m).分析記事 • Jan 05e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although...お知らせ • Dec 27e-therapeutics Ordinary Shares to Cease to Trade on the OTCQX Best Market in the United Statese-therapeutics plc announced that, with effect from 31 December 2023, its ordinary shares ("Ordinary Shares") will cease to trade on the OTCQX Best Market in the United States ("OTCQX"). The Company's Ordinary Shares began trading on OTCQX on 24 September 2021, but there has been limited trading since that date. As such, the expenses associated with the Company's Ordinary Shares trading on OTCQX outweigh the benefits for e-therapeutics shareholders. The Ordinary Shares will continue to be admitted to trading on AIM as the Company's primary market.New Risk • Nov 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (UK£340k revenue, or US$421k). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (UK£67.3m market cap, or US$83.3m).最新情報をもっと見るRecent updatesお知らせ • Apr 11e-therapeutics plc Considers Switching Its Listing to New YorkShares of e-therapeutics plc fell 12% after the company said it is considering switching its listing to New York, a move that would deal a further blow to the London bourse following a spate of defections in recent months. The provider of digital technology for drug discovery also said April 10, 2024 that it raised GBP 28.9 million ($36.6 million) via a high-premium share subscription by its two largest shareholders. Shares at 0752 GMT were down 1.50 pence at 11.0 pence. They are currently down 25% over the past 12 months. e-Therapeutics is seeking shareholder approval to cancel its current listing on London's junior AIM, saying it doesn't believe it accurately reflects its value and is a hindrance to its plans given a significant reduction in liquidity and access to capital. It also said it believes a listing on U.S. Nasdaq will provide a higher valuation, but cautioned that there is no certainty the listing will be achievable in any given time frame. The London delisting plan has the support of shareholders owing 46.68% of its shares, it said. e-Therapeutics has called a general meeting for April 29 to seek approval to delist its shares, and if approved, expects cancellation to become effective from May 9.お知らせ • Apr 10e-therapeutics plc, Annual General Meeting, Apr 29, 2024e-therapeutics plc, Annual General Meeting, Apr 29, 2024, at 11:30 Coordinated Universal Time. Location: Unit 4B, Floor 4, 4 Kingdom Street, Paddington Central London United KingdomNew Risk • Feb 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: UK£77.1m (US$97.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (UK£340k revenue, or US$430k). Minor Risk Market cap is less than US$100m (UK£77.1m market cap, or US$97.7m).分析記事 • Jan 05e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although...お知らせ • Dec 27e-therapeutics Ordinary Shares to Cease to Trade on the OTCQX Best Market in the United Statese-therapeutics plc announced that, with effect from 31 December 2023, its ordinary shares ("Ordinary Shares") will cease to trade on the OTCQX Best Market in the United States ("OTCQX"). The Company's Ordinary Shares began trading on OTCQX on 24 September 2021, but there has been limited trading since that date. As such, the expenses associated with the Company's Ordinary Shares trading on OTCQX outweigh the benefits for e-therapeutics shareholders. The Ordinary Shares will continue to be admitted to trading on AIM as the Company's primary market.New Risk • Nov 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (UK£340k revenue, or US$421k). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (UK£67.3m market cap, or US$83.3m).お知らせ • Oct 20e-therapeutics plc to Report First Half, 2024 Results on Oct 26, 2023e-therapeutics plc announced that they will report first half, 2024 results on Oct 26, 2023お知らせ • Sep 21E-Therapeutics plc Announces Senior Management Updatee-therapeutics plc announces that Michael Bretherton has stepped down from his role as interim CFO and will now focus on his role as a Non-Executive Director of the Company. Timothy Bretherton, Director of Finance and Operations, will assume the CFO role (non-board) with immediate effect. Timothy is an experienced finance leader having held multiple senior roles prior to joining e-therapeutics in May 2022. He has a strong practical background previously gained over 12 years in operational and finance roles including four years as a consultant at PwC and three years as an auditor at Mazars. He has a degree in Economics from the University of Leicester and is a member of the Institute of Chartered Accountants in England and Wales.分析記事 • Sep 13We Think e-therapeutics (LON:ETX) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • May 11e-therapeutics plc, Annual General Meeting, Jul 18, 2023e-therapeutics plc, Annual General Meeting, Jul 18, 2023, at 11:30 Coordinated Universal Time. Location: 4 Kingdom Street Paddington, London W2 6BD London United Kingdom Agenda: To receive the accounts for the financial year ended 31 January 2023 together with the Directors' Report and the Auditor's Report for that period; to re-elect Ali Mortazavi as a Director of the Company, who has been a Director since 10 February 2020 and was last re-elected by shareholders in March 2020; to re-appoint Crowe U.K. LLP as the Auditor of the Company; to authorise the Directors to set the remuneration of the Auditor of the Company; and to consider other matters.Reported Earnings • May 07Full year 2023 earnings released: UK£0.015 loss per share (vs UK£0.017 loss in FY 2022)Full year 2023 results: UK£0.015 loss per share. Net loss: UK£8.27m (loss widened 2.5% from FY 2022).分析記事 • Mar 27e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Non-Executive Chairman Trevor Jones is the most experienced director on the board, commencing their role in 2015. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Sep 30First half 2023 earnings released: UK£0.007 loss per share (vs UK£0.005 loss in 1H 2022)First half 2023 results: UK£0.007 loss per share (further deteriorated from UK£0.005 loss in 1H 2022). Net loss: UK£3.81m (loss widened 37% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 87% per year, which means it is well ahead of earnings.分析記事 • Jul 07We Think e-therapeutics (LON:ETX) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • May 17e-therapeutics plc, Annual General Meeting, Jul 19, 2022e-therapeutics plc, Annual General Meeting, Jul 19, 2022, at 11:30 Coordinated Universal Time. Location: 4 Kingdom Street Paddington London United KingdomReported Earnings • May 05Full year 2022 earnings released: UK£0.016 loss per share (vs UK£0.01 loss in FY 2021)Full year 2022 results: UK£0.016 loss per share (down from UK£0.01 loss in FY 2021). Net loss: UK£8.07m (loss widened 119% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 129% per year, which means it is well ahead of earnings.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Non-Executive Chairman Trevor Jones is the most experienced director on the board, commencing their role in 2015. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Oct 28First half 2022 earnings released: UK£0.005 loss per share (vs UK£0.006 loss in 1H 2021)First half 2022 results: Net loss: UK£2.79m (loss widened 19% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth.Recent Insider Transactions • Oct 28CEO & Director recently bought UK£100k worth of stockOn the 26th of October, Ahmad Mortazavi bought around 275k shares on-market at roughly UK£0.36 per share. This was the largest purchase by an insider in the last 3 months. This was Ahmad's only on-market trade for the last 12 months.分析記事 • Oct 28We're Not Worried About e-therapeutics' (LON:ETX) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. By way of example, e-therapeutics...Reported Earnings • May 15Full year 2021 earnings released: UK£0.01 loss per share (vs UK£0.009 loss in FY 2020)Full year 2021 results: Net loss: UK£3.68m (loss widened 57% from FY 2020). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 15e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £22.5 million.e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £22.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 93,750,000 Price\Range: £0.24 Transaction Features: Regulation S; Subsequent Direct Listing分析記事 • Mar 21Have Insiders Been Buying e-therapeutics plc (LON:ETX) Shares?We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...お知らせ • Mar 01e-Therapeutics plc Announces Board Changese-therapeutics plc announced the following changes to its Board of Directors. With immediate effect, the role of Executive Chairman and Chief Executive will be split so that Professor Trevor Jones, an Independent Non-Executive Director of the Company since 2015, will assume the role of Independent Non-Executive Chairman and Ali Mortazavi will continue in his role as Chief Executive Officer. Trevor has over 40 years' experience in the pharmaceutical and biotechnology industries as well as in academia. He has held significant roles including Director of Allergan Inc. from 2005 to 2015 and R&D Director of The Wellcome Foundation from 1987 to 1994, where he was responsible for the development of AZT, Zovirax, Lamictal and Malarone. He is Visiting Professor at King's College, London and holds honorary degrees and Gold Medals from seven universities.分析記事 • Feb 14We Think e-therapeutics (LON:ETX) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. By way of example...Is New 90 Day High Low • Feb 04New 90-day high: UK£0.22The company is up 67% from its price of UK£0.13 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 15% over the same period.お知らせ • Feb 03e-Therapeutics plc Announces Addition of its RNAi Platform as a Therapeutic Drug Modalitye-therapeutics plc announced the addition of its RNAi platform as a therapeutic drug modality. The Company has recently filed a patent application related to the chemistry of novel GalNAc-conjugated siRNAs (short interfering RNA), an important element of its RNAi platform that enables specific hepatocyte targeting for liver gene silencing. In addition, a number of siRNA constructs have been designed with potentially beneficial safety and potency profiles and additional patent applications are expected to be filed shortly. The company believes that the new patent applications, combined with know-how, will provide a significant competitive advantage in RNAi. The new constructs will include features to minimise potential microRNA off-target effects, thermally destabilising regions of the siRNA for reduced toxicity and important position-specific stabilisation chemistries to improve potency. Multiple in vitro and in vivo experiments are underway to test these constructs with contract research organizations in Germany and China.分析記事 • Jan 10Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?The big shareholder groups in e-therapeutics plc ( LON:ETX ) have power over the company. Generally speaking, as a...Is New 90 Day High Low • Jan 09New 90-day high: UK£0.21The company is up 37% from its price of UK£0.15 on 09 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.お知らせ • Dec 11e-therapeutics plc Announces Results of Experimental Testing on the Compounds for the Treatment of Covid-19 Identified Using Its Proprietary Network-Driven Drug Discovery (Ndd) Platforme-therapeutics plc announced the results of experimental testing on the compounds for the treatment of COVID-19 identified using its proprietary Network-driven Drug Discovery (NDD) platform. In March 2020, the Company announced its intention to deploy its network biology platform to identify clinical stage compounds that either singly or in combination could be repurposed rapidly to treat COVID-19. To approach this by focussing on therapeutic strategies that target host systems, thereby minimising the risk of resistance and potentially being effective for the treatment of other viral infections. From previous work using network models of SIRS (Systemic inflammatory response syndrome) seen in indications such as sepsis, had identified a class of small molecule compounds, a mechanism and target that was able to silence the 'cytokine storm' generated in human blood cells by a range of inflammatory triggers. In March 2020, undertook an in silico analysis of data sets from human cells infected with SARS-CoV-2 and generated network models of the cellular machinery that the virus had 'hijacked'. Analysis of both SIRS work and the SARS-CoV-2 networks revealed a key common process which was simultaneously important to the virus and the hyperinflammatory response. Platform predicted that inhibition of the same target, GRP94, that was effective in suppressing hyperinflammation would also be effective in disrupting the virus's ability to replicate. In May 2020, small molecule compounds predicted by platform were tested in validated SARS-CoV-2 in vitro assays at WuXi AppTech. These compounds showed potent anti-inflammatory and anti-viral activity. Report here that in vitro assays have confirmed in silico predictions and have identified a clear mechanism, target and clinical stage compounds. These compounds are active against GRP94 and have anti-inflammatory and anti-viral activity against Sars-CoV-2. This activity generalises to other alpha and beta coronaviruses and is expected to be generically applicable, raising the prospect of utility against both existing coronaviruses that cause serious disease such as SARS and MERS and against new emergent strains of coronavirus. The clinical stage compounds identified have been developed in humans for alternative indications and have an established safety profile in man. These, and other selective compounds sharing this target, could be rapidly deployed into clinical trials to treat patients with serious Covid-19 disease. Given mechanistic insights, it would also be feasible to develop novel, highly selective drugs against GRP94. Continue to work on repurposable combinations using platform and have compound combinations currently in testing.分析記事 • Dec 06Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...Reported Earnings • Oct 13First half earnings releasedOver the last 12 months the company has reported total losses of UK£3.41m, with losses widening by 9.7% from the prior year.お知らせ • Oct 13e-therapeutics plc Announces Appointment of Ali Mortazavi as CEOe-therapeutics plc announced the appointment of Ali Mortazavi as Chief Executive Officer. He will also retain his position as Chairman of the Company. The Board currently consists of one Executive Director and two Non-Executive Directors.お知らせ • Oct 07e-therapeutics plc to Report First Half, 2020 Results on Oct 12, 2020e-therapeutics plc announced that they will report first half, 2020 results on Oct 12, 2020お知らせ • Sep 28e-therapeutics plc Announces Executive Changese-therapeutics plc announced the expansion of its Scientific Advisory Board with the appointment of Bill Harte and Professor John Mattick. The appointments follow the establishment of the SAB in May of 2020 with the initial appointment of Paul Burke as Chair following the Company's expansion into RNA interference (RNAi) as a therapeutic modality to pursue drug discovery outcomes. Dr. Bill Harte is a pharmaceutical veteran and serial entrepreneur with more than 30 years in both research and executive positions. He currently serves as the Chief Translational Officer at the Case Western Reserve University School of Medicine advising and translating preclinical programs into patients.お知らせ • Jul 09e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £0.75 million.e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £0.75 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,250,000 Price\Range: £0.12株主還元ETXGB BiotechsGB 市場7D-4.3%2.8%1.4%1Y-29.3%26.9%19.5%株主還元を見る業界別リターン: ETX過去 1 年間で26.9 % の収益を上げたUK Biotechs業界を下回りました。リターン対市場: ETXは、過去 1 年間で19.5 % のリターンを上げたUK市場を下回りました。価格変動Is ETX's price volatile compared to industry and market?ETX volatilityETX Average Weekly Movement10.2%Biotechs Industry Average Movement9.4%Market Average Movement5.8%10% most volatile stocks in GB Market12.0%10% least volatile stocks in GB Market3.1%安定した株価: ETXの株価は、 UK市場と比較して過去 3 か月間で変動しています。時間の経過による変動: ETXの weekly volatility ( 10% ) は過去 1 年間安定していますが、依然としてUKの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200134Ahmad Mortazaviwww.etherapeutics.co.ukもっと見るe-therapeutics plc 基礎のまとめe-therapeutics の収益と売上を時価総額と比較するとどうか。ETX 基礎統計学時価総額UK£52.59m収益（TTM）-UK£10.06m売上高(TTM)UK£340.00k154.7xP/Sレシオ-5.2xPER（株価収益率ETX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ETX 損益計算書（TTM）収益UK£340.00k売上原価UK£0売上総利益UK£340.00kその他の費用UK£10.40m収益-UK£10.06m直近の収益報告Jul 31, 2023次回決算日該当なし一株当たり利益（EPS）-0.017グロス・マージン100.00%純利益率-2,957.65%有利子負債／自己資本比率0%ETX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/05/10 04:14終値2024/05/08 00:00収益2023/07/31年間収益2023/01/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋e-therapeutics plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 11e-therapeutics plc Considers Switching Its Listing to New YorkShares of e-therapeutics plc fell 12% after the company said it is considering switching its listing to New York, a move that would deal a further blow to the London bourse following a spate of defections in recent months. The provider of digital technology for drug discovery also said April 10, 2024 that it raised GBP 28.9 million ($36.6 million) via a high-premium share subscription by its two largest shareholders. Shares at 0752 GMT were down 1.50 pence at 11.0 pence. They are currently down 25% over the past 12 months. e-Therapeutics is seeking shareholder approval to cancel its current listing on London's junior AIM, saying it doesn't believe it accurately reflects its value and is a hindrance to its plans given a significant reduction in liquidity and access to capital. It also said it believes a listing on U.S. Nasdaq will provide a higher valuation, but cautioned that there is no certainty the listing will be achievable in any given time frame. The London delisting plan has the support of shareholders owing 46.68% of its shares, it said. e-Therapeutics has called a general meeting for April 29 to seek approval to delist its shares, and if approved, expects cancellation to become effective from May 9.
お知らせ • Apr 10e-therapeutics plc, Annual General Meeting, Apr 29, 2024e-therapeutics plc, Annual General Meeting, Apr 29, 2024, at 11:30 Coordinated Universal Time. Location: Unit 4B, Floor 4, 4 Kingdom Street, Paddington Central London United Kingdom
New Risk • Feb 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: UK£77.1m (US$97.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (UK£340k revenue, or US$430k). Minor Risk Market cap is less than US$100m (UK£77.1m market cap, or US$97.7m).
分析記事 • Jan 05e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although...
お知らせ • Dec 27e-therapeutics Ordinary Shares to Cease to Trade on the OTCQX Best Market in the United Statese-therapeutics plc announced that, with effect from 31 December 2023, its ordinary shares ("Ordinary Shares") will cease to trade on the OTCQX Best Market in the United States ("OTCQX"). The Company's Ordinary Shares began trading on OTCQX on 24 September 2021, but there has been limited trading since that date. As such, the expenses associated with the Company's Ordinary Shares trading on OTCQX outweigh the benefits for e-therapeutics shareholders. The Ordinary Shares will continue to be admitted to trading on AIM as the Company's primary market.
New Risk • Nov 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (UK£340k revenue, or US$421k). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (UK£67.3m market cap, or US$83.3m).
お知らせ • Apr 11e-therapeutics plc Considers Switching Its Listing to New YorkShares of e-therapeutics plc fell 12% after the company said it is considering switching its listing to New York, a move that would deal a further blow to the London bourse following a spate of defections in recent months. The provider of digital technology for drug discovery also said April 10, 2024 that it raised GBP 28.9 million ($36.6 million) via a high-premium share subscription by its two largest shareholders. Shares at 0752 GMT were down 1.50 pence at 11.0 pence. They are currently down 25% over the past 12 months. e-Therapeutics is seeking shareholder approval to cancel its current listing on London's junior AIM, saying it doesn't believe it accurately reflects its value and is a hindrance to its plans given a significant reduction in liquidity and access to capital. It also said it believes a listing on U.S. Nasdaq will provide a higher valuation, but cautioned that there is no certainty the listing will be achievable in any given time frame. The London delisting plan has the support of shareholders owing 46.68% of its shares, it said. e-Therapeutics has called a general meeting for April 29 to seek approval to delist its shares, and if approved, expects cancellation to become effective from May 9.
お知らせ • Apr 10e-therapeutics plc, Annual General Meeting, Apr 29, 2024e-therapeutics plc, Annual General Meeting, Apr 29, 2024, at 11:30 Coordinated Universal Time. Location: Unit 4B, Floor 4, 4 Kingdom Street, Paddington Central London United Kingdom
New Risk • Feb 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: UK£77.1m (US$97.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (UK£340k revenue, or US$430k). Minor Risk Market cap is less than US$100m (UK£77.1m market cap, or US$97.7m).
分析記事 • Jan 05e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although...
お知らせ • Dec 27e-therapeutics Ordinary Shares to Cease to Trade on the OTCQX Best Market in the United Statese-therapeutics plc announced that, with effect from 31 December 2023, its ordinary shares ("Ordinary Shares") will cease to trade on the OTCQX Best Market in the United States ("OTCQX"). The Company's Ordinary Shares began trading on OTCQX on 24 September 2021, but there has been limited trading since that date. As such, the expenses associated with the Company's Ordinary Shares trading on OTCQX outweigh the benefits for e-therapeutics shareholders. The Ordinary Shares will continue to be admitted to trading on AIM as the Company's primary market.
New Risk • Nov 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (UK£340k revenue, or US$421k). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (UK£67.3m market cap, or US$83.3m).
お知らせ • Oct 20e-therapeutics plc to Report First Half, 2024 Results on Oct 26, 2023e-therapeutics plc announced that they will report first half, 2024 results on Oct 26, 2023
お知らせ • Sep 21E-Therapeutics plc Announces Senior Management Updatee-therapeutics plc announces that Michael Bretherton has stepped down from his role as interim CFO and will now focus on his role as a Non-Executive Director of the Company. Timothy Bretherton, Director of Finance and Operations, will assume the CFO role (non-board) with immediate effect. Timothy is an experienced finance leader having held multiple senior roles prior to joining e-therapeutics in May 2022. He has a strong practical background previously gained over 12 years in operational and finance roles including four years as a consultant at PwC and three years as an auditor at Mazars. He has a degree in Economics from the University of Leicester and is a member of the Institute of Chartered Accountants in England and Wales.
分析記事 • Sep 13We Think e-therapeutics (LON:ETX) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • May 11e-therapeutics plc, Annual General Meeting, Jul 18, 2023e-therapeutics plc, Annual General Meeting, Jul 18, 2023, at 11:30 Coordinated Universal Time. Location: 4 Kingdom Street Paddington, London W2 6BD London United Kingdom Agenda: To receive the accounts for the financial year ended 31 January 2023 together with the Directors' Report and the Auditor's Report for that period; to re-elect Ali Mortazavi as a Director of the Company, who has been a Director since 10 February 2020 and was last re-elected by shareholders in March 2020; to re-appoint Crowe U.K. LLP as the Auditor of the Company; to authorise the Directors to set the remuneration of the Auditor of the Company; and to consider other matters.
Reported Earnings • May 07Full year 2023 earnings released: UK£0.015 loss per share (vs UK£0.017 loss in FY 2022)Full year 2023 results: UK£0.015 loss per share. Net loss: UK£8.27m (loss widened 2.5% from FY 2022).
分析記事 • Mar 27e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Non-Executive Chairman Trevor Jones is the most experienced director on the board, commencing their role in 2015. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Sep 30First half 2023 earnings released: UK£0.007 loss per share (vs UK£0.005 loss in 1H 2022)First half 2023 results: UK£0.007 loss per share (further deteriorated from UK£0.005 loss in 1H 2022). Net loss: UK£3.81m (loss widened 37% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 87% per year, which means it is well ahead of earnings.
分析記事 • Jul 07We Think e-therapeutics (LON:ETX) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • May 17e-therapeutics plc, Annual General Meeting, Jul 19, 2022e-therapeutics plc, Annual General Meeting, Jul 19, 2022, at 11:30 Coordinated Universal Time. Location: 4 Kingdom Street Paddington London United Kingdom
Reported Earnings • May 05Full year 2022 earnings released: UK£0.016 loss per share (vs UK£0.01 loss in FY 2021)Full year 2022 results: UK£0.016 loss per share (down from UK£0.01 loss in FY 2021). Net loss: UK£8.07m (loss widened 119% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 129% per year, which means it is well ahead of earnings.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Non-Executive Chairman Trevor Jones is the most experienced director on the board, commencing their role in 2015. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Oct 28First half 2022 earnings released: UK£0.005 loss per share (vs UK£0.006 loss in 1H 2021)First half 2022 results: Net loss: UK£2.79m (loss widened 19% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth.
Recent Insider Transactions • Oct 28CEO & Director recently bought UK£100k worth of stockOn the 26th of October, Ahmad Mortazavi bought around 275k shares on-market at roughly UK£0.36 per share. This was the largest purchase by an insider in the last 3 months. This was Ahmad's only on-market trade for the last 12 months.
分析記事 • Oct 28We're Not Worried About e-therapeutics' (LON:ETX) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. By way of example, e-therapeutics...
Reported Earnings • May 15Full year 2021 earnings released: UK£0.01 loss per share (vs UK£0.009 loss in FY 2020)Full year 2021 results: Net loss: UK£3.68m (loss widened 57% from FY 2020). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 15e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £22.5 million.e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £22.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 93,750,000 Price\Range: £0.24 Transaction Features: Regulation S; Subsequent Direct Listing
分析記事 • Mar 21Have Insiders Been Buying e-therapeutics plc (LON:ETX) Shares?We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
お知らせ • Mar 01e-Therapeutics plc Announces Board Changese-therapeutics plc announced the following changes to its Board of Directors. With immediate effect, the role of Executive Chairman and Chief Executive will be split so that Professor Trevor Jones, an Independent Non-Executive Director of the Company since 2015, will assume the role of Independent Non-Executive Chairman and Ali Mortazavi will continue in his role as Chief Executive Officer. Trevor has over 40 years' experience in the pharmaceutical and biotechnology industries as well as in academia. He has held significant roles including Director of Allergan Inc. from 2005 to 2015 and R&D Director of The Wellcome Foundation from 1987 to 1994, where he was responsible for the development of AZT, Zovirax, Lamictal and Malarone. He is Visiting Professor at King's College, London and holds honorary degrees and Gold Medals from seven universities.
分析記事 • Feb 14We Think e-therapeutics (LON:ETX) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. By way of example...
Is New 90 Day High Low • Feb 04New 90-day high: UK£0.22The company is up 67% from its price of UK£0.13 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 15% over the same period.
お知らせ • Feb 03e-Therapeutics plc Announces Addition of its RNAi Platform as a Therapeutic Drug Modalitye-therapeutics plc announced the addition of its RNAi platform as a therapeutic drug modality. The Company has recently filed a patent application related to the chemistry of novel GalNAc-conjugated siRNAs (short interfering RNA), an important element of its RNAi platform that enables specific hepatocyte targeting for liver gene silencing. In addition, a number of siRNA constructs have been designed with potentially beneficial safety and potency profiles and additional patent applications are expected to be filed shortly. The company believes that the new patent applications, combined with know-how, will provide a significant competitive advantage in RNAi. The new constructs will include features to minimise potential microRNA off-target effects, thermally destabilising regions of the siRNA for reduced toxicity and important position-specific stabilisation chemistries to improve potency. Multiple in vitro and in vivo experiments are underway to test these constructs with contract research organizations in Germany and China.
分析記事 • Jan 10Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?The big shareholder groups in e-therapeutics plc ( LON:ETX ) have power over the company. Generally speaking, as a...
Is New 90 Day High Low • Jan 09New 90-day high: UK£0.21The company is up 37% from its price of UK£0.15 on 09 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.
お知らせ • Dec 11e-therapeutics plc Announces Results of Experimental Testing on the Compounds for the Treatment of Covid-19 Identified Using Its Proprietary Network-Driven Drug Discovery (Ndd) Platforme-therapeutics plc announced the results of experimental testing on the compounds for the treatment of COVID-19 identified using its proprietary Network-driven Drug Discovery (NDD) platform. In March 2020, the Company announced its intention to deploy its network biology platform to identify clinical stage compounds that either singly or in combination could be repurposed rapidly to treat COVID-19. To approach this by focussing on therapeutic strategies that target host systems, thereby minimising the risk of resistance and potentially being effective for the treatment of other viral infections. From previous work using network models of SIRS (Systemic inflammatory response syndrome) seen in indications such as sepsis, had identified a class of small molecule compounds, a mechanism and target that was able to silence the 'cytokine storm' generated in human blood cells by a range of inflammatory triggers. In March 2020, undertook an in silico analysis of data sets from human cells infected with SARS-CoV-2 and generated network models of the cellular machinery that the virus had 'hijacked'. Analysis of both SIRS work and the SARS-CoV-2 networks revealed a key common process which was simultaneously important to the virus and the hyperinflammatory response. Platform predicted that inhibition of the same target, GRP94, that was effective in suppressing hyperinflammation would also be effective in disrupting the virus's ability to replicate. In May 2020, small molecule compounds predicted by platform were tested in validated SARS-CoV-2 in vitro assays at WuXi AppTech. These compounds showed potent anti-inflammatory and anti-viral activity. Report here that in vitro assays have confirmed in silico predictions and have identified a clear mechanism, target and clinical stage compounds. These compounds are active against GRP94 and have anti-inflammatory and anti-viral activity against Sars-CoV-2. This activity generalises to other alpha and beta coronaviruses and is expected to be generically applicable, raising the prospect of utility against both existing coronaviruses that cause serious disease such as SARS and MERS and against new emergent strains of coronavirus. The clinical stage compounds identified have been developed in humans for alternative indications and have an established safety profile in man. These, and other selective compounds sharing this target, could be rapidly deployed into clinical trials to treat patients with serious Covid-19 disease. Given mechanistic insights, it would also be feasible to develop novel, highly selective drugs against GRP94. Continue to work on repurposable combinations using platform and have compound combinations currently in testing.
分析記事 • Dec 06Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...
Reported Earnings • Oct 13First half earnings releasedOver the last 12 months the company has reported total losses of UK£3.41m, with losses widening by 9.7% from the prior year.
お知らせ • Oct 13e-therapeutics plc Announces Appointment of Ali Mortazavi as CEOe-therapeutics plc announced the appointment of Ali Mortazavi as Chief Executive Officer. He will also retain his position as Chairman of the Company. The Board currently consists of one Executive Director and two Non-Executive Directors.
お知らせ • Oct 07e-therapeutics plc to Report First Half, 2020 Results on Oct 12, 2020e-therapeutics plc announced that they will report first half, 2020 results on Oct 12, 2020
お知らせ • Sep 28e-therapeutics plc Announces Executive Changese-therapeutics plc announced the expansion of its Scientific Advisory Board with the appointment of Bill Harte and Professor John Mattick. The appointments follow the establishment of the SAB in May of 2020 with the initial appointment of Paul Burke as Chair following the Company's expansion into RNA interference (RNAi) as a therapeutic modality to pursue drug discovery outcomes. Dr. Bill Harte is a pharmaceutical veteran and serial entrepreneur with more than 30 years in both research and executive positions. He currently serves as the Chief Translational Officer at the Case Western Reserve University School of Medicine advising and translating preclinical programs into patients.
お知らせ • Jul 09e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £0.75 million.e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £0.75 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,250,000 Price\Range: £0.12
